XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

NCT03218787 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

2047

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Lesions

Interventions

DEVICE: XIENCE
DRUG: DAPT

Sponsor

Abbott Medical Devices